Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Hopefully there will be more buying leading up to Thursday. MM are playing games with the price though. "Uniq's Q3 interim management statement for the period from 1 July 2009 to 30 September 2009 will be announced on 15 October 2009."
Brian Howlett, CEO of Lombard Medical, commented: "This PMA filing is another important step towards U.S. market approval for our lead product, the Aorfix™, which we believe offers significant advantages compared with currently marketed stent grafts for the treatment of abdominal aortic aneurysms (“AAAs”). The Company is also developing the next phase of Aorfix™ pre-marketing activities, with the goal of establishing the scientific and clinical reputation of the device and laying down solid foundations for a successful launch post-PMA.” -End- Enquiries: Lombard Medical Technologies PLC Tel: 01235 750 800 Simon Neathercoat, Non-executive Chairman Brian Howlett, Chief Executive Officer Tim Hall, Finance Director Financial Dynamics Tel: 020 7831 3113 Jonathan Birt / Susan Quigley Nomura Code Tel: 020 7776 1200 Juliet Thompson / Richard Potts
FDA acceptance of the first of six modules of PMA filing for Aorfix™ London, UK, 2 September 2009 – Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company, announces that the U.S. Food and Drug Administration (“FDA”) has accepted and closed the first of six modules of the Company's Pre-market Approval (“PMA”) filing plan for Aorfix™. The first module is one of four modules covering FDA required preclinical testing for the device. Preclinical testing covers device material biocompatibility and toxicity, sterilization, packaging, shelf-life and device functional testing. The Company is planning to submit the next three PMA modules with preclinical testing before the end of H1 2010. The Company’s manufacturing approval module is set for submission early in the second half of 2010, followed by the clinical data module in Q4 2010. The modular PMA process is designed to assist medical device companies and the FDA to review completed testing while the clinical data is ongoing. It allows for content of the PMA application to be broken into well-delineated components for concurrent assessments by FDA reviewers. The review timeframe is 90 days for each module which is then closed and "accepted" upon satisfactory review of the data. Each accepted module becomes part of the completed PMA application. Brian Howlett, CEO of Lombard Medical, commented: "This PMA filing is
http://www.yaletrials.org/clinicalTrials/displayTrial.asp?nctID=NCT00522535&pageID=1&row=2
Bought some last year as a punt at this price and they tanked, I was planning to get out if they broke even. I,m not sure what to do now though as some posters on advfn suggest it could go to 20p or higher if they get the right partners on board.